<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Hematological VitroScreen

Patient primary never-passaged Hematological models for screening.

Industry-leading Hematologic Model Screening

Champions' Hematological VitroScreens offer a quick, cost-effective solution to test your therapeutics in an ex vivo hematologic assay evaluating efficacy and mechanisms of action in primary patient samples.

  • Largest primary hematological repository of Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphoblastic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM) models
  • Well-characterized models featuring patient responses, clinical annotation, NGS data (WES and RNASeq), deep phenotyping using flow cytometry, proteomics, and phospho-proteomics datasets available in Lumin

Data-Driven Insights to Accelerate Your Hematologic Program

All models are hand-picked for each VitroScreen and have been characterized for ex vivo cell viability and several standard of care drug dose responses, available in Lumin.
 
Our standard endpoint is a cell viability assessment by CellTiter-Glo®, and additional optional endpoints are available during each VitroScreen enrollment period to maximize the insight our partners can derive from each experiment. 
VitroScreen results in AML and B-ALL models in response to Standards of Care.

Hematological VitroScreen Endpoints

 

imaging
IHC
Flow
NGS
Western Blot
Luminex
Colony
DNA
Proteomics
Cell

"Champions Oncology’s Hematological VitroScreen has become a critical tool in our research arsenal. The platform’s high throughput and precise results have significantly improved our ability to screen and analyze potential therapies for blood cancers."

___________________________________________________

CSO, Biotech Company

"The Hematological VitroScreen from Champions Oncology has significantly enhanced our ability to evaluate drug efficacy and safety. The platform’s comprehensive data and high sensitivity have provided us with crucial insights into hematologic malignancies and drug interactions."

___________________________________________________

Senior Scientist, Pharmaceutical Company

 

The Autologous AML Platform is an ex vivo co-culture assay developed and optimized to interrogate the responses of your immuno-oncology (IO) drugs in only 4 days using primary patient models.

 

Tab Imges_Medium21